Aligos Therapeutics Reaches Analyst Target Price
December 24, 2020 at 08:22 AM EST
In recent trading, shares of Aligos Therapeutics Inc (ALGS) have crossed above the average analyst 12-month target price of $31.50, changing hands for $32.74/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..